Azar: Price Referencing Is Only Option To Introduce Competition

By Rachel Cohrs / November 15, 2018 at 2:41 PM
HHS Secretary Alex Azar doubled down on the Trump administration’s controversial plan to lower Medicare Part B drug costs by relying on international reference prices in a speech to the Commonwealth Fund International Symposium on Health Care Wednesday. Brand-drug manufacturers have strongly opposed the policy, which was unveiled in an advance notice of proposed rulemaking last month and could evolve into a proposed rule within months. “We have looked for alternative ways to introduce a market-based competitive pricing model, but...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.